Healius Ltd (ASX:HLS)

A$ 1.64 -0.035 (-2.09%) Market Cap: 1.19 Bil Enterprise Value: 2.73 Bil PE Ratio: 0 PB Ratio: 1.14 GF Score: 64/100

Half Year 2024 Healius Ltd Earnings Call Transcript
Feb 27, 2024

A$1.27 (-8.66%)

Earnings
Healius Ltd Annual Shareholders Meeting Transcript
Nov 28, 2023
Healius Ltd Conference Call Transcript
Nov 22, 2023
Full Year 2023 Healius Ltd Earnings Call Transcript
Aug 30, 2023

A$2.7 (+7.75%)

Earnings
Australian Clinical Labs Ltd To Merge with Healius Ltd Call Transcript
Mar 19, 2023
Half Year 2023 Healius Ltd Earnings Call Transcript
Feb 27, 2023

A$2.6 (-4.10%)

Earnings
Healius Ltd Annual Shareholders Meeting Transcript
Oct 20, 2022
Full Year 2022 Healius Ltd Earnings Call Transcript
Aug 30, 2022

A$3.54 (+3.51%)

Earnings
Half Year 2022 Healius Ltd Earnings Call Transcript
Feb 23, 2022

A$4.08 (+5.25%)

Earnings
Healius Ltd to Acquire Agilex Biolabs Pty Ltd Call Transcript
Dec 17, 2021
Full Year 2021 Healius Ltd Earnings Call Transcript
Aug 30, 2021

A$4.32 (-7.34%)

Earnings
Half Year 2021 Healius Ltd Earnings Call Transcript
Feb 24, 2021

A$3.69 (+2.31%)

Earnings
Healius Ltd Sustainable Improvements Program and Capital Management Plans Call Transcript
Dec 08, 2020
Healius Ltd Annual Shareholders Meeting Transcript
Oct 22, 2020
Full Year 2020 Healius Ltd Earnings Call Transcript
Aug 21, 2020

A$3.04 (+0.31%)

Earnings
Healius Ltd Sales of Medical Centres and Market Update Presentation Transcript
Jun 15, 2020
Half Year 2020 Healius Ltd Earnings Call Transcript
Feb 26, 2020

A$2.94 (+15.22%)

Earnings
Healius Ltd Annual Shareholders Meeting Transcript
Nov 24, 2019
Full Year 2019 Healius Ltd Earnings Call Transcript
Aug 16, 2019

A$2.71 (+5.02%)

Earnings

Healius Ltd to Acquire Agilex Biolabs Pty Ltd Call Transcript

Dec 17, 2021 / 03:00AM GMT

Release Date Price: A$4.74 (-3.03%)

Transcript

Malcolm W. Parmenter

Healius Limited - MD, CEO & Director

Thank you, and good afternoon, everybody. Thank you for making the time in the last few days leading up to Christmas. We apologize for making announcements like this right on the cusp of Christmas, and these sorts of things tend to have their own agenda, so they happen when they happen.

So look, I'm sure you're all looking forward to a breakeven if it's affected by the various travel requirements we have in place across the states. As you would appreciate from the current COVID case numbers, particularly in New South Wales, we, here at Healius, are experiencing another new year period of high levels of testing in our laboratories. And on that point, I'd like to take this opportunity to thank our dedicated team, who have done so much and continue to do so much to help the national effort against the COVID-19 pandemic.

And so first, an exciting and a relevant moment for us to announce a transaction that will significantly grow and evolve our capabilities and portfolio, especially as a laboratory services provider. Healius has

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.